Breaking News Instant updates and real-time market news.

TROV

Trovagene

$3.29

-0.05 (-1.50%)

, ABBV

AbbVie

$78.10

0.54 (0.70%)

08:03
04/23/19
04/23
08:03
04/23/19
08:03

Trovagene announces preclinical data evaluating onvansertib with venetoclax

Trovagene (TROV) announced preclinical data that evaluated the effect of combining onvansertib with venetoclax in an AML cell model known to be resistant to venetoclax, or Venclexta of AbbVie (ABBV). This combination demonstrated synergy with a significant decrease in tumor cell viability. This data further supports Trovagene's ongoing onvansertib clinical development program in patients with relapsed/refractory AML, for which there are limited treatment options and the prognosis is poor. The Company is currently conducting a Phase 1b/2 open-label clinical trial of onvansertib in combination with standard-of-care chemotherapy in patients with relapsed or refractory AML at nine sites across the U.S. and recently presented encouraging safety and preliminary efficacy data at the American Association for Clinical Research conference.

TROV

Trovagene

$3.29

-0.05 (-1.50%)

ABBV

AbbVie

$78.10

0.54 (0.70%)

  • 24

    Apr

  • 25

    Apr

  • 28

    Apr

  • 03

    May

  • 03

    May

  • 04

    May

  • 18

    May

  • 31

    May

  • 05

    Jun

TROV Trovagene
$3.29

-0.05 (-1.50%)

06/18/18
MAXM
06/18/18
UPGRADE
Target $3
MAXM
Buy
Trovagene upgraded to Buy at Maxim on positive PCM-075 news
As reported earlier Maxim analyst Jason McCarthy upgraded Trovagene to Buy from Hold with a price target of $3, citing the positive news from the company's lead drug candidate PCM-075 as well as its completion of a capital raise. The analyst notes that Trovagene's balance sheet now gives it a run rate into the second half of 2019 while the PCM-075 studies progress toward their next set of catalysts. Given the suspension of the financing overhang, McCarthy says the company's potential justifies a more constructive stance.
06/18/18
06/18/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Francesca's (FRAN) upgraded to Buy from Neutral at B. Riley FBR with analyst Susan Anderson saying she has increased confidence in the company's turnaround following meetings with management. 2. Chevron (CVX) upgraded to Outperform from Market Perform at Raymond James with analyst Pavel Molchanov saying Chevron offers relatively more leverage than most peers to higher oil prices, which should reach cyclical highs over the next 6 to 12 months, while low WTI exposure maximizes earnings and free cash flow generation. 3. Trovagene (TROV) upgraded to Buy from Hold at Maxim with analyst Jason McCarthy citing the positive news from the company's lead drug candidate PCM-075 as well as its completion of a capital raise. 4. RBS (RBS) upgraded to Buy from Hold at Investec. 5. Teva (TEVA) upgraded to Market Perform from Underperform at Wells Fargo with analyst David Maris citing a "positive meeting" with Teva's CEO Kundefinedre Schultz and CFO Mike McClellan in Israel. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/07/19
NBLE
01/07/19
INITIATION
Target $5.2
NBLE
Outperform
Trovagene initiated with an Outperform at Noble Financial
Noble Financial analyst Ahu Demir initiated Trovagene with an Outperform rating and $5.20 price target, stating that investors remain skeptical of PLK1 targeting but he foresees upside potential and likes TrovaGene's Onvansertib. He believes further data will be valuable to demonstrate anti-tumor activity and the safety profile of Onvansertib, Demir tells investors.
03/01/19
MAXM
03/01/19
NO CHANGE
Target $8
MAXM
Buy
Trovagene price target lowered to $8 from $18 at Maxim
Maxim analyst Jason McCarthy lowered his post-split price target for Trovagene to $8 from $18, which reflects dilution associated with future capital raises. The analyst keeps a Buy rating on the shares ahead of a "busy" American Association for Cancer Research annual meeting for the company in late March. Trovagene now has three funded clinical trials with Onvansertib, and as updates are provided in 2019, they should, if positive, support a higher valuation, McCarthy tells investors in a research note.
ABBV AbbVie
$78.10

0.54 (0.70%)

03/25/19
ARGS
03/25/19
DOWNGRADE
ARGS
Hold
AbbVie downgraded to Hold from Buy at Argus
03/25/19
03/25/19
DOWNGRADE

Hold
AbbVie downgraded to Hold from Buy at Argus
As previously reported, Argus analyst David Toung downgraded AbbVie to Hold, saying its flagship program Humira "no longer looks invulnerable to competition from biosimilars in Europe and other overseas markets." The analyst notes that Humira is also faced with "indirect competition from newer drugs that have an alternative mechanism of action" compared to Humira's anti-TNF class. Toung further cites AbbVie's clinical setback with Venclexta, which highlights the risks for the company as it develops a pipeline aimed to offset the expected decline in Humira sales.
03/26/19
WBLR
03/26/19
UPGRADE
WBLR
Outperform
William Blair upgrades Vertex to Outperform after 'subpar' competitor data
William Blair analyst Y. Katherine Xu upgraded Vertex Pharmaceuticals (VRTX) to Outperform from Market Perform on expectations the company's cystic fibrosis franchise will continue dominating after Proteostasis (PTI) reported disappointing triplet data. Proteostasis' triplet efficacy falls short of the high bar set by the Vertex triples, Xu tells investors in a research note. While Proteostasis is starting a Phase II study of the triplet that would include a higher PTI-808 dose and test a longer duration aiming to optimize response with data out around year-end 2019, the chance of it matching or exceeding Vertex triple efficacy is "very low," contends the analyst. With both Galapagos (GLPG)/AbbVie (ABB) and Proteostasis having shown "subpar data," Xu is upgrading Vertex shares to Outperform and raised her fair value estimate for the shares to $222 from $178. The analyst maintains her high probability of success of a Vertex triple combo reaching the cystic fibrosis market at 90% and ascribe peak sales of $10.2B, up from $8.9 billion previously.
04/11/19
EVER
04/11/19
INITIATION
Target $30
EVER
Outperform
Myovant Sciences initiated with an Outperform at Evercore ISI
Evercore ISI analyst Ravi Mehrotra initiated Myovant Sciences (MYOV) with an Outperform rating and a price targets of $30. The analyst says the company's lead program relugolix has been clinically de-risked with near-term pivotal data readouts. Mehrotra is modeling revenues of $944M for the program by 2023 thanks to its "commercial advantage of a one-a-day pill" and the "second-mover leverage of competitor AbbVie's (ABBV) efforts to raise awareness and diagnosis" in woman's health market.

TODAY'S FREE FLY STORIES

NFLX

Netflix

$291.40

-5.47 (-1.84%)

, DIS

Disney

$131.70

-4.37 (-3.21%)

11:55
08/24/19
08/24
11:55
08/24/19
11:55
Periodicals
Football season is back, key moment for TV future, Barron's says »

On Sept. 5, when the…

NFLX

Netflix

$291.40

-5.47 (-1.84%)

DIS

Disney

$131.70

-4.37 (-3.21%)

FOXA

Fox Corp.

$31.76

-1.29 (-3.90%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$42.47

-1.29 (-2.95%)

CBS

CBS

$41.39

-2.06 (-4.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 23

    Sep

  • 27

    Oct

AAPL

Apple

$202.73

-9.82 (-4.62%)

, AMZN

Amazon.com

$1,752.00

-52 (-2.88%)

09:03
08/24/19
08/24
09:03
08/24/19
09:03
Periodicals
Costco the most 'woke' company out there, Barron's says »

Earlier this week, the…

AAPL

Apple

$202.73

-9.82 (-4.62%)

AMZN

Amazon.com

$1,752.00

-52 (-2.88%)

BLK

BlackRock

$407.29

-11.55 (-2.76%)

WMT

Walmart

$110.83

-1.07 (-0.96%)

COST

Costco

$274.16

-5.7 (-2.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 25

    Sep

  • 03

    Oct

  • 27

    Oct

  • 13

    Nov

  • 14

    Nov

MMM

3M

$155.84

-5.04 (-3.13%)

08:58
08/24/19
08/24
08:58
08/24/19
08:58
Periodicals
3M stock still not looking like a bargain, Barron's says »

3M shares are down by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

ULTA

Ulta Beauty

$322.34

-12.5 (-3.73%)

08:56
08/24/19
08/24
08:56
08/24/19
08:56
Periodicals
Ulta Beauty bucking downbeat retail trends, Barron's says »

Ulta Beauty has been one…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 25

    Sep

CMCSK

Comcast

$0.00

(0.00%)

, CMCSA

Comcast

$42.47

-1.29 (-2.95%)

08:49
08/24/19
08/24
08:49
08/24/19
08:49
Periodicals
Roku working for investors, Barron's says »

The streaming war…

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$42.47

-1.29 (-2.95%)

DIS

Disney

$131.70

-4.37 (-3.21%)

NFLX

Netflix

$291.40

-5.47 (-1.84%)

AAPL

Apple

$202.73

-9.82 (-4.62%)

ROKU

Roku

$137.77

-1.35 (-0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 05

    Sep

  • 23

    Sep

  • 27

    Oct

NSRGY

Nestle

$0.00

(0.00%)

08:44
08/24/19
08/24
08:44
08/24/19
08:44
Periodicals
Nestle stock looking appetizing after big gain, Barron's says »

Nestle is having a great…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$291.40

-5.47 (-1.84%)

, DIS

Disney

$131.70

-4.37 (-3.21%)

08:39
08/24/19
08/24
08:39
08/24/19
08:39
Periodicals
Football season is back, key moment for TV future, Barron's says »

On Sept. 5, when the…

NFLX

Netflix

$291.40

-5.47 (-1.84%)

DIS

Disney

$131.70

-4.37 (-3.21%)

FOXA

Fox Corp.

$31.76

-1.29 (-3.90%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$42.47

-1.29 (-2.95%)

CBS

CBS

$41.39

-2.06 (-4.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 23

    Sep

  • 27

    Oct

AMZN

Amazon.com

$1,752.00

-52 (-2.88%)

, FDX

FedEx

$151.94

-6.17 (-3.90%)

08:05
08/24/19
08/24
08:05
08/24/19
08:05
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMZN

Amazon.com

$1,752.00

-52 (-2.88%)

FDX

FedEx

$151.94

-6.17 (-3.90%)

UPS

UPS

$111.29

-3.91 (-3.39%)

F

Ford

$8.76

-0.27 (-2.99%)

GM

General Motors

$36.06

-1.19 (-3.19%)

DDAIF

Daimler AG

$0.00

(0.00%)

HMC

Honda

$22.90

-0.32 (-1.38%)

TM

Toyota

$127.94

-1.69 (-1.30%)

VWAGY

Volkswagen

$0.00

(0.00%)

AAPL

Apple

$202.73

-9.82 (-4.62%)

FB

Facebook

$177.69

-4.39 (-2.41%)

TWTR

Twitter

$41.01

-1.16 (-2.75%)

GOOGL

Alphabet Class A

$1,154.66

-35.75 (-3.00%)

GOOG

Alphabet

$1,151.72

-36.81 (-3.10%)

ADM

Archer Daniels

$37.44

-0.48 (-1.27%)

REGI

Renewable Energy

$11.65

0.61 (5.53%)

GPRE

Green Plains

$7.34

-0.68 (-8.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 15

    Sep

  • 17

    Sep

  • 17

    Sep

  • 18

    Sep

  • 19

    Sep

  • 23

    Sep

  • 24

    Sep

  • 23

    Oct

  • 23

    Oct

  • 27

    Oct

  • 13

    Nov

AMAT

Applied Materials

$45.12

-1.92 (-4.08%)

, AMD

AMD

$29.55

-2.35 (-7.37%)

04:55
08/24/19
08/24
04:55
08/24/19
04:55
Conference/Events
MUFG Securities to hold a tour »

MUFG Securities Tech Tour…

AMAT

Applied Materials

$45.12

-1.92 (-4.08%)

AMD

AMD

$29.55

-2.35 (-7.37%)

ANET

Arista Networks

$223.35

-3.84 (-1.69%)

CHKP

Check Point

$106.84

-2.36 (-2.16%)

CSCO

Cisco

$46.65

-1.55 (-3.22%)

EQIX

Equinix

$549.81

-4.27 (-0.77%)

FLEX

Flex

$9.72

-0.54 (-5.26%)

INTC

Intel

$44.97

-1.79 (-3.83%)

NVDA

Nvidia

$162.51

-8.93 (-5.21%)

OTEX

OpenText

$38.54

-0.57 (-1.46%)

PYPL

PayPal

$106.08

-2.66 (-2.45%)

RNG

RingCentral

$141.50

-0.86 (-0.60%)

SQ

Square

$61.65

-3 (-4.64%)

STX

Seagate

$46.96

-0.62 (-1.30%)

TWLO

Twilio

$127.90

-2.585 (-1.98%)

V

Visa

$175.24

-4.91 (-2.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 28

    Aug

  • 28

    Aug

  • 29

    Aug

  • 05

    Sep

  • 06

    Sep

  • 09

    Sep

  • 10

    Sep

  • 16

    Sep

  • 17

    Sep

  • 18

    Sep

  • 19

    Sep

  • 10

    Oct

  • 15

    Oct

  • 24

    Oct

  • 27

    Oct

  • 06

    Nov

  • 13

    Nov

  • 13

    Nov

  • 12

    Dec

  • 16

    Dec

DB

Deutsche Bank

$6.98

-0.19 (-2.65%)

, COF

Capital One

$83.06

-2.68 (-3.13%)

17:57
08/23/19
08/23
17:57
08/23/19
17:57
Periodicals
Deutsche Bank, Capital One won't say if they have Trump's tax returns, NYP says »

Deutsche Bank (DB) and…

DB

Deutsche Bank

$6.98

-0.19 (-2.65%)

COF

Capital One

$83.06

-2.68 (-3.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

MXIM

Maxim Integrated

$52.14

-2.42 (-4.44%)

17:53
08/23/19
08/23
17:53
08/23/19
17:53
Hot Stocks
Maxim Integrated's Jain sells 12,683 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

GLD

SPDR Gold Shares

$144.15

2.77 (1.96%)

17:42
08/23/19
08/23
17:42
08/23/19
17:42
Hot Stocks
SPDR Gold Shares holdings rise to 859.83MT to 854.84MT »

This is the fourth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUMN

Golden Minerals

$0.27

0.0159 (6.38%)

17:33
08/23/19
08/23
17:33
08/23/19
17:33
Hot Stocks
Golden Minerals receives noncompliance notice from NYSE »

Golden Minerals announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DMPI

DelMar Pharmaceuticals

$0.77

0.0047 (0.61%)

17:25
08/23/19
08/23
17:25
08/23/19
17:25
Hot Stocks
Intracoastal Capital reports 9.99% passive stake in DelMar Pharmaceuticals »

Intracoastal Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTN

Raytheon

$180.58

-6.44 (-3.44%)

17:22
08/23/19
08/23
17:22
08/23/19
17:22
Hot Stocks
Raytheon awarded $534M Army contract »

Raytheon was awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UHAL

Amerco

$339.43

-2.97 (-0.87%)

17:21
08/23/19
08/23
17:21
08/23/19
17:21
Hot Stocks
Amerco announces special cash dividend of 50c per share »

The dividend will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTLA

Intellia Therapeutics

$15.77

-1.08 (-6.41%)

17:20
08/23/19
08/23
17:20
08/23/19
17:20
Syndicate
Breaking Syndicate news story on Intellia Therapeutics »

Intellia Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$183.42

-4.19 (-2.23%)

17:19
08/23/19
08/23
17:19
08/23/19
17:19
Hot Stocks
General Dynamics awarded $1.08B Navy contract modification »

General Dynamics has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVLN

Novelion Therapeutics

$0.66

-0.0523 (-7.37%)

17:17
08/23/19
08/23
17:17
08/23/19
17:17
Hot Stocks
Stonepine Capital reports 6.1% passive stake in Novelion Therapeutics »

Stonepine Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$376.85

-8.91 (-2.31%)

17:14
08/23/19
08/23
17:14
08/23/19
17:14
Hot Stocks
Lockheed Martin awarded $2.43B Navy contract modification »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCS

OncoSec

$1.84

-0.03 (-1.60%)

17:14
08/23/19
08/23
17:14
08/23/19
17:14
Syndicate
Breaking Syndicate news story on OncoSec »

OncoSec files $50M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNXP

Tonix Pharmaceuticals

$0.42

-0.0249 (-5.60%)

17:09
08/23/19
08/23
17:09
08/23/19
17:09
Syndicate
Breaking Syndicate news story on Tonix Pharmaceuticals »

Tonix Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$284.86

-7.5 (-2.57%)

17:08
08/23/19
08/23
17:08
08/23/19
17:08
General News
Trump to raises tariff rates on Chinese goods, CNBC says »

U.S. President Donald…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$284.86

-7.5 (-2.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATIS

Attis Industries

$1.03

-0.08 (-7.21%)

17:06
08/23/19
08/23
17:06
08/23/19
17:06
Hot Stocks
Attis Industries provides update on status of Nasdaq listing »

Attis Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVEO

Civeo

$1.32

-0.07 (-5.04%)

17:04
08/23/19
08/23
17:04
08/23/19
17:04
Syndicate
Breaking Syndicate news story on Civeo »

Civeo files $300M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.